There has been a groundbreaking shift in the approach to Alzheimer’s disease in recent years, transitioning from diagnosis to treatment for the first time. With this change comes the need for significant modification of diagnostic protocols and clinical workflows. Asked for her thoughts on the future of diagnosis in Alzheimer’s disease, Lyduine Collij, PhD, BioFINDER group, Lund University, Lund, Sweden, comments on the necessity of a biological diagnosis, brought about by the availability of disease-modifying therapies. Many unknowns remain regarding how to optimize these treatments on an individual level, including the optimal dosing schedule and how to predict the likelihood of amyloid-related imaging abnormalities (ARIA). Additionally, there’s a growing need to incorporate amyloid-PET quantification into clinical practice, as it is being used more and more for clinical trial enrolment and efficacy assessments. If treatments are shown to be most successful in certain centiloid score ranges, quantification might become essential in daily practice, further revolutionizing Alzheimer’s disease diagnosis and treatment strategies. These data support the validity of amyloid-PET. This interview took place at the CTAD 2023 conference in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
